Quarterly deal volumes have been above 200 for almost five years now and Q2 2019’s level was well above the 2014-2018 average. Although there were no megadeals, non-megadeal-related value growth was up over Q1 2019. Overall trading multiples growth continued for the ninth quarter, but Labs / Imaging / Pharmacy multiples continued to decline. Long-term deal drivers remain largely unchanged.
Health Services Deals Leader, PwC US
Deals Director, PwC US